pharmacotherapy, vocational rehabilitation, social skills training, daily living skills training, illness management, independent living skills training, and patient empowerment program. For CR+PR group, CR treatment was provided adjunctive to their PR program described above. CR treatment consisted of 24 sessions that occurred twice a week for 1 h/session for over 3 months. The PSSCogRehab software program which was translated in Korea and Lumosity cognitive enhancement game were utilized for CR training. Participants in PR-only group were also received same psychiatric rehabilitation program, that specific training on neurocognitive functioning was not included. Nineteen participants who were undergoing TAU without CR or PR were evaluated pre-and post-treatment. Results: No group differences were found in key demographical variables, premorbid IQ, psychiatric characteristics or baseline neurocognitive functioning at the pre-treatment. CR was easily provided and well received (drop-out rates = 5.3%) by mid-aged and older psychiatric inpatients. the CR + PR group showed greater post-treatment performance on both WCST total errors and WCST %CL compared with the PR-only group (WCST total errors: mean difference = 12.28, p = 0.026; WCST %CL: mean difference = 16.47, p = 0.017) and TAU group (WCST total errors: mean difference = 14.00, p = 0.015; WCST %CL: mean difference = 16.24, p = 0.023). However, no group differences were found on WCST total errors and WCST %CL between the PR-only and TAU groups. No group differences were found for processing speed, attention, verbal working memory or cognitive flexibility.
F56. IMPACT OF SIDE EFFECTS DUE TO SECOND-GENERATION ANTIPSYCHOTICS

H. Lundbeck A/S
Background: In patients with schizophrenia, antipsychotic medications, including second-generation antipsychotics, may cause many side-effects (SE) often leading to treatment discontinuation, and possible relapse as a consequence. The impact of treatments on patientcentered outcomes such as health-related quality of life (HRQOL) is less well understood. Even less well understood is the impact of side effects on patient-centered outcomes such as daily functioning and HRQOL. Therefore, the study's primary goal was to gain a deeper understanding of the impacts of SEs of second generation antipsychotics on patients' day to day functioning. Methods: A cross-sectional, web-based, patient-reported survey was fielded in the United States between July and November 2017. The final survey included patient socio-demographics, a quality of life measure (Quality of Life Enjoyment and Satisfaction Questionnaire Short Form, Q-LES-Q-SF), questions on treatment satisfaction, SEs experienced (Glasgow Antipsychotic Side-Effect Scale, GASS), and questions about the impact of SEs on functioning and emotions. Patients were recruited through patient advocacy and support groups, and medical research panels. Patient inclusion criteria: Self-reported schizophrenia diagnosis; 18 to 65 years old; stable for at least one month at time of screening; prescribed a second-generation antipsychotic medication for 1-12 months; the final sample consisted of those individuals who reported experiencing one or more sideeffects based on the GASS. Results: The total sample (n=180) had a mean age of 35 (range 18-61) years old, of which 58.3% were females. Approximately a quarter (27.8%) of the sample had a college degree or higher; 69.4% identified as White, followed by 16.7% Black/ African American, and 6.1% Native Hawaiian/ Pacific Islanders. Most prevalent SEs reported on the GASS were 'difficulty sleeping' (81.1%), 'feeling sleepy during the day' (77.2%), 'dry mouth' (70.6%), and 'feeling restless (60.6%). The SEs most commonly reported as distressing, for those patients experiencing that SE, were difficulty passing urine (23.3%), and feeling drugged/like a zombie (19.4%). The minimum impact from SEs on daily functioning was 53.2 on a 0-100 Visual Analogue Scale (higher number reflects more negative impact on daily functioning; 0=no impact and 100=very highly impacted). Across the SEs further probed about, the most severe impact was on one's 'ability to get or do a job'; specifically, for the SEs 'shaky hands or arms' the mean impact was 76.1, followed by 69.8 for restlessness. 'Problems enjoying sex' had the greatest effect on one's 'intimate relationships' (mean 74.8), and feeling drugged/ like a zombie had the greatest effect on one's 'ability to concentrate' (mean 70.2). Discussion: The study indicates the importance of incorporating the patient with schizophrenia's perspective when assessing SE experiences and impact on functioning due to second generation antipsychotic agents. Findings suggest that both activating SEs (restlessness) and sedating SEs (feeling drugged and sleepiness) have pronounced undesirable impact on daily patient functioning. 
Beijing Anding Hospital of Capital Medical University
Background: A significant percentage of women taking antipsychotic medication may be suffering from abnormal menses during their treatment, which influences both fertility and adherence to medication. It is particularly common in patients prescripted with risperidone. This study aimed to identify the risk factors for abnormal menses in female individuals with schizophrenia during risperidone treatment, especially the relationship between abnormal menses and the dose or the length of the medicine. Methods: This study used a retrospective data. 202 female patients diagnosed with schizophrenia using risperidone were screened. Doses and length of treatment with risperidone were various. 38 were excluded for their menstrual irregularities before treatment, in which 4 amenorrhea and 15 menopause. 164 female patients included, but 3 of them absent of data. 161 female patients included in analyses at last. Results: Of the 161 patients, 119 were eumenorrhea up to our analyses, and other 42 abnormal menses, including 23 menstrual irregularities, 8 amenorrhea and 11 oligomenorrhea. There was no statistical difference in age (32.0 ± 8.6 vs. 31.4 ± 10.1) (years), education (12.2 ± 2.3 vs. 12.6 ± 2.2) (years), age at onset 26.7 ± 8.0 vs. 24.8 ± 8.4) (years), duration of illness (5.8 ± 5.2 vs. 7.0 ± 7.7) (years), PANSS total score (37.2 ± 8.8 vs. 38.1 ± 7.0) between normal group and abnormal group. There was also no statistical difference in risperidone dose at baseline (4.3 ± 0.7 vs. 4.3 ± 0.5) (mg/d), total treatment in this episode (5.3 ± 4.7 vs. 5.4 ± 5.4) (months), overall length of risperidone treatment in this episode (86.7 ± 62.0 vs. 98.6 ± 73.5) (days), length of risperidone treatment at optimal therapeutic dose (63.0 ± 64.5 vs. 51.3 ± 26.7) (days). Discussion: Some research suggests antipsychotic-induced abnormal menses is related to medication-induced high prolactinemia level and low estradiol level pretreatment. But few study reports the relationship between abnormal menses and the dose or the length of the medicine. This study got negative results, which suggest the occurrence of abnormal menses widely depend on individual quality rather than the length and the dose of the antipsychotic. But there are some limits in the study. First, the dosage range among these subjects were relatively narrow. And then, the length of risperidone treatment is generally short. In the next step of research, we will improve these two points.
F58 Background: As existing treatments for negative symptoms in schizophrenia have limited empirical support, development of effective treatments for negative symptoms in schizophrenia is in urgent need. Behavioral activation (BA), which is an evidence-based treatment for depression, is a promising candidate treatment for negative symptoms as it proved its feasibility and preliminary efficacy in non-randomized controlled trial for community dwelling individuals with chronic schizophrenia (Choi et al., 2015; Mairs et al., 2011) . The primary purpose of the current study was to investigate whether BA would improve negative symptoms as compared with treatment as usual (TAU) for community dwelling individuals with chronic schizophrenia in a multi-site randomized controlled trial. In addition, we explored whether BA would improve other psychiatric symptoms, quality of life and neuro-cognitive functioning. Methods: For multi-site trials, mental health professionals were trained with BA manual (Choi et al., 2015) and their fidelity was checked by the authors. BA was delivered in a group format once a week for 10 weeks. Participants aged 18 years or older were recruited from community mental health centers and day hospitals in Seoul and Gyeonggi-do area. A total of seventy-two patients with negative symptoms of schizophrenia were randomly assigned into either BA+TAU or TAU. As a primary outcome, negative symptoms were measured using clinical interviews (e.g., BNSS, CAINS, PANSS negative symptoms factor) and self-report questionnaires (i.e., MAP-SR) before and after the 10-week treatments. The secondary outcome measures included other psychiatric symptoms, quality of life, and neuro-cognitive assessment. Results: BA was well accepted by community dwelling individuals with chronic schizophrenia (drop-out rates of BA+TAU and TAU, 10% and 14%, respectively). Intention-to-treat analyses indicated that compared to TAU condition, BA+TAU group showed greater improvement in negative symptoms, as measured by CAINS, BNSS, and PANSS negative symptom factor (Time*Group interaction effects, F=7.476, p<.01 for CAINS total; F=5.663, p<.05 for BNSS total; F=6.092, p<.05 for PANSS negative symptoms factor). In addition, the results indicated group differences in favor of BA+TAU on the PANSS general psychopathology factor and the Quality of Life, but not neurocognitive functioning (Time*Group interaction effects, F=5.660, p<.05 for PANSS general psychopathology factor; F=7.541, p<.01 for QOL total).
Discussion:
The results of the current study demonstrate the feasibility and the efficacy of BA+TAU for negative symptoms of community dwelling individuals with chronic schizophrenia as compared to TAU when delivered by BA trained mental health professionals. Thus, it is speculated that BA is an effective adjunct psychosocial approach to usual comprehensive psychiatric rehabilitation for negative symptoms. Since the current study is ongoing and follow-up data will be available by the time of presentation at SIRS 2018, it will be examined whether benefits of BA would be maintained 3 months after the termination of 10-week BA treatment. 
Utrecht University
Background: The ability to perceive, recognize and process own and others' emotions is crucial for efficient and effective social communication. Many different tasks have been used to investigate impairments herein in patients with schizophrenia. Evidence suggests that perception, discrimination and recognition of affective facial expressions are impaired in schizophrenia patients. Importantly, not everyone may interpret the same facial expression similarly. People match their internal representation of specific facial expressions to perceived faces and variation in these internal representations may result in a distortion of social reality. The impairments in face and/or emotion processing and the bias toward a more negative experience may be causally related to degradation of the internal representation itself or to disturbances in the higher-order evaluation of visual input against functionally intact internal representations. In an attempt to develop ways of visualizing an individuals' internal representation of an emotional face on a computer screen, we set out to visualize the representation of a male and a female face.
Methods:
We use a data-driven technique, i.e. reverse correlation image classification (RCIC), which makes it possible to visualize internal representations of faces on computer screens. Participants judge noisy images of faces that are created by superimposing random noise on a single constant base face. The random noise distorts the base face at the pixel level, generating facial variation across stimuli that is fully unconstrained and unaffected by researchers' a priori expectations. The participants' responses to a large number of faces are used to model the facial information that was idiosyncratically diagnostic for the judgments. This analysis yields a classification image (CI) for each participant, which visualizes the facial characteristics that drive judgments of emotional expressions (i.e., their internal representation). We introduce an objective metric, i.e. infoVal, using gender as proof-ofprinciple. infoVal quantifies the probability that an observed CI was not generated by a random process and is equivalent to a modified z score. First, we test the association between infoVal and more common markers of data quality, i.e. the subjective recognizability, objective discriminability and test-retest reliability of CIs (convergent validity). Second, we use RCIC to investigate and reconstruct the mental representation of trustworthiness as expressed on the face in 32 patients with schizophrenia and 39 controls. Results: Subjective ratings showed that male and female CIs were more strongly associated with masculinity and femininity, respectively, when infoVal scores where high (p<.001). Second, infoVal scores were highly correlated with test-retest reliability, i.e., higher scores corresponded with higher test-retest reliability (p<1x10-13). Preliminary analyses of the RCIC task on the internal representation of trustworthy and untrustworthy faces showed that both patients and controls are capable of performing the task adequately. Data-driven multidimensional scaling of the classification images implicate 3 clusters of images, reflecting untrustworthy, neutral, and trustworthy faces. These first analyses suggest that there is no evidence for differences in internal representation of (un)trustworthy faces between patients and controls. Discussion: We showed how infoVal scores can facilitate the interpretation of CIs. This opens the way to comprehensively investigate internal representations of emotional faces in patients with schizophrenia. 
F60. INFLAMMATORY MARKERS AND
